Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma

Authors: Songhua Fan, Delong Meng, Tao Xu, Yuanyuan Chen, Jingkun Wang, Xiaoying Li, Hongyan Chen, Daru Lu, Juxiang Chen, Qing Lan

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

The clinical significance of SLC7A7 expression remains unclear. In this study, we aimed to explore whether SLC7A7 expression in tumor tissues could be used to assess subsequent prognosis in patients with glioblastoma (GBM). A total of 119 patients with pathologically confirmed GBM and 16 normal controls were recruited for this study. The expression of SLC7A7 in GBM and normal tissues was evaluated by immunohistochemistry in tissue microarrays and quantitative real-time PCR. Kaplan–Meier method and Cox’s proportional hazards model were used in survival analysis. Compared with normal tissues, GBM specimens had significantly increased expression of SLC7A7 at both mRNA and protein levels (both P < 0.05). Moreover, multivariate analysis confirmed that overexpression of SLC7A7 was a significant and independent indicator for predicting poor prognosis. Our results suggest, for the first time, that overexpression of SLC7A7 is correlated with worse outcomes in patients with GBM. SLC7A7 plays a critical role in GBM carcinogenesis and may be a potential prognosis predictor of GBM.
Literature
1.
Rock K, McArdle O, Forde P, et al. A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol. 2012;85:e729–33.
2.
Porter KR, McCarthy BJ, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12:520–7.PubMedCrossRef
3.
4.
Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15.PubMedCrossRef
5.
Ganapathy V, Thangaraju M, Prasad PD, et al. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121:29–40.PubMedCrossRef
6.
He L, Vasiliou K, Nebert DW, et al. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics. 2009;3:195–206.PubMedCrossRef
7.
Torrents D, Estevez R, Pineda M, et al. Identification and characterization of a membrane protein (y + L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y + L. A candidate gene for lysinuric protein intolerance. J Biol Chem. 1998;273:32437–45.PubMedCrossRef
8.
Omidi Y, Barar J, Ahmadian S, et al. Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochem Funct. 2008;26:381–91.PubMedCrossRef
9.
Wang Q, Bailey CG, Ng C, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 2011;71:7525–36.PubMedCrossRef
10.
Cheng L, Lu W, Kulkarni B, et al. Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. Gynecol Oncol. 2010;117:159–69.PubMedCrossRef
11.
Xie L, Song X, Yu J, et al. Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer. J Cancer Res Clin Oncol. 2011;137:1739–47.PubMedCrossRef
12.
Agnelli L, Forcato M, Ferrari F, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011;17:7402–12.PubMedCrossRef
13.
Xiang ZL, Zeng ZC, Fan J, et al. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res. 2011;17:5463–72.PubMedCrossRef
14.
Cui YZ, Wu JM, Zong MJ, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124:1614–21.PubMedCrossRef
15.
Ohuchida K, Mizumoto K, Lshikawa N, et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 2005;11:7785–93.PubMedCrossRef
16.
Sun B, Chu D, Li W, et al. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009;94:213–9.PubMedCrossRef
17.
Zhang S, Lu J, Zhao X, et al. A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis. 2010;31:1251–8.PubMedCrossRef
18.
Wang Y, Li S, Chen L, et al. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518–25.PubMedCrossRef
19.
Li S, Yan C, Huang L, et al. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol. 2012;14:109–16.PubMedCrossRef
20.
McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.CrossRef
Metadata
Title
Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma
Authors
Songhua Fan
Delong Meng
Tao Xu
Yuanyuan Chen
Jingkun Wang
Xiaoying Li
Hongyan Chen
Daru Lu
Juxiang Chen
Qing Lan
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0384-8

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue

Original Paper

Rural–urban disparities of breast cancer patients in China

Original Paper

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

Original Paper

Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions

Original Paper

HLA-G expression in acute lymphoblastic leukemia: a significant prognostic tumor biomarker

Original Paper

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

Original Paper

Hepatic angiomyolipoma: clinical, imaging and pathological features in 178 cases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits